BioRestorative Therapies (BRTX) 10-K 29 Mar 24 2023 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2023	Mar. 28, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-37603
Entity Registrant Name	BIORESTORATIVE THERAPIES, INC.
Entity Central Index Key	0001505497
Entity Tax Identification Number	30-1341024
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	40 Marcus Drive
Entity Address, Address Line Two	Suite 1
Entity Address, City or Town	Melville
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11747
City Area Code	(631)
Local Phone Number	760-8100
Title of 12(b) Security	Common Stock $0.0001 par value
Trading Symbol	BRTX
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 13,663,719
Entity Bankruptcy Proceedings, Reporting Current	true
Entity Common Stock, Shares Outstanding		6,769,919
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	688
Auditor Name	Marcum LLP
Auditor Location	Marlton, New Jersey

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 884,377	$ 1,713,772
Investments held in marketable securities	10,181,618	13,035,636
Accounts receivable	19,300	16,000
Prepaid expenses and other current assets	305,231	363,082
Total Current Assets	11,390,526	15,128,490
Property and equipment, net	356,055	261,003
Right-of-use assets	151,447	241,760
Intangible assets, net	713,692	803,438
Total Assets	12,611,720	16,434,691
Current Liabilities:
Accounts payable	189,389	170,902
Accrued expenses and other current liabilities	711,686	130,072
Lease liability, current portion	162,317	139,328
Total Current Liabilities	1,063,392	440,302
Lease liability, net of current portion		162,317
Total Liabilities	1,063,392	602,619
Commitments and contingencies
Stockholders’ Equity:
Common stock, $0.0001 par value; 75,000,000 shares authorized; 4,706,917 and 3,677,775 shares issued and outstanding at December 31, 2023 and 2022, respectively	471	369
Additional paid-in capital	178,590,256	168,457,418
Accumulated deficit	(167,056,381)	(152,640,897)
Total Stockholders’ Equity	11,548,328	15,832,072
Total Liabilities and Stockholders’ Equity	12,611,720	16,434,691
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock, value	$ 13,982	$ 15,182

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	4,706,917	3,677,775
Common stock, shares outstanding	4,706,917	3,677,775
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized	1,543,158	1,543,158
Preferred stock, shares issued	1,398,158	1,518,158
Preferred stock, shares outstanding	1,398,158	1,518,158

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues, net	$ 145,800	$ 119,800
Operating Expenses:
Research and development	4,034,591	3,513,352
General and administrative	11,331,983	15,580,473
Total Operating Expenses	15,366,574	19,093,825
Loss From Operations	(15,220,774)	(18,974,025)
Other Income:
Interest income	(552,293)	(11,650)
Gain on PPP loan forgiveness		(250,000)
Grant income	(83,333)	(110,518)
Other income	(169,664)	(107,088)
Total Other Income	(805,290)	(479,256)
Net Loss	$ (14,415,484)	$ (18,494,769)
Net Loss Per Share - Basic	$ (3.42)	$ (5.11)
Net Loss Per Share - Diluted	$ (3.42)	$ (5.11)
Weighted Average Common Shares Outstanding - Basic	4,218,347	3,617,858
Weighted Average Common Shares Outstanding - Diluted	4,218,347	3,617,858

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Preferred Stock [Member] Series A Convertible Preferred Stock [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021	$ 15,432		$ 353	$ 155,727,292	$ (134,146,128)	$ 21,596,949
Balance, shares at Dec. 31, 2021	1,543,158		3,520,391
Issuance of Series B Convertible Preferred Stock in exchange for Series A Convertible Preferred Stock	$ (15,432)	$ 15,432
Issuance of Series B Convertible Preferred Stock in exchange for Series A Convertible Preferred Stock, shares	(1,543,158)	1,543,158
Warrants issued in connection with license exclusivity agreement				117,030		117,030
Conversion of Series B Convertible Preferred Stock into common stock		$ (250)	$ 3	247
Conversion of Series B Convertible Preferred Stock into common stock, shares		(25,000)	25,000
Stock-based compensation:
Restricted share units			$ 11	4,735,097		4,735,108
Restricted share units, shares			116,486
Options				7,741,864		7,741,864
Common stock			$ 2	135,888		135,890
Common stock, shares			15,898
Net loss					(18,494,769)	(18,494,769)
Balance at Dec. 31, 2022		$ 15,182	$ 369	168,457,418	(152,640,897)	15,832,072
Balance, shares at Dec. 31, 2022		1,518,158	3,677,775
Conversion of Series B Convertible Preferred Stock into common stock		$ (1,200)	$ 12	1,188
Conversion of Series B Convertible Preferred Stock into common stock, shares		(120,000)	120,000
Stock-based compensation:
Restricted share units			$ 9	4,633,655		4,633,664
Restricted share units, shares			89,840
Options				3,141,803		3,141,803
Common stock				7,500		7,500
Common stock, shares			1,442
Net loss					(14,415,484)	(14,415,484)
Issuance and sale of common stock, net of issuance costs			$ 81	2,348,692		2,348,773
Issuance and sale of common stock, net of issuance costs, shares			817,860
Balance at Dec. 31, 2023		$ 13,982	$ 471	$ 178,590,256	$ (167,056,381)	$ 11,548,328
Balance, shares at Dec. 31, 2023		1,398,158	4,706,917

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash Flows From Operating Activities:
Net loss	$ (14,415,484)	$ (18,494,769)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	165,735	120,545
Dividend and interest income	(569,068)	(76,004)
Stock-based compensation	7,782,967	12,612,862
Gain on PPP loan forgivesness		(250,000)
Non-cash lease expense	90,313	160,122
Changes in operating assets and liabilities:
Accounts receivable	(3,300)	(11,000)
Prepaid expenses and other current assets	57,851	73,099
Accounts payable	18,487	120,075
Accrued expenses and other current liabilities	581,616	(4,898)
Lease liability	(139,328)	(163,132)
Net Cash Used In Operating Activities	(6,430,211)	(5,913,100)
Cash Flows From Investing Activities:
Sale of marketable securities	20,964,373	9,492,304
Purchase of marketable securities	(17,541,287)	(22,451,936)
Purchase of intangible assets		(175,000)
Purchases of equipment	(171,043)	(265,223)
Net Cash Provided By (Used In) Investing Activities	3,252,043	(13,399,855)
Cash Flows From Financing Activities:
Net proceeds from issuance of common stock in ATM transactions	497,353
Net proceeds from issuance of common stock in registered direct offering	1,853,990
Net Cash Provided By Financing Activities	2,351,343
Net Decrease In Cash and Cash Equivalents	(826,825)	(19,312,955)
Cash and Cash Equivalents - Beginning of the Year	1,713,772	21,026,727
Cash and Cash Equivalents - End of the Year	886,947	1,713,772
Supplemental Disclosures of Cash Flow Information:
Interest
Income taxes
Non-cash investing and financing activities:
Warrants issued as consideration for intangible assets		$ 117,030

ORGANIZATION, LIQUIDITY AND BUS

ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS	Note 1 - ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS Corporate History BioRestorative Therapies, Inc. has one wholly-owned subsidiary, Stem Pearls, LLC (“Stem Pearls”). BioRestorative Therapies, Inc. and its subsidiary are referred to collectively as “BRT” or the “Company”. On December 23, 2022, the Company reincorporated from Delaware to Nevada by filing Articles of Incorporation with the state of Nevada. The reincorporation was structured as a statutory merger. Liquidity The accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and satisfying liabilities in the normal course of business. For the year ended December 31, 2023, the Company had a net loss of $ 14.4 7.8 6.4 Based on cash on hand as of the date these financial statements were issued, which includes $ 8.1 Current funds noted above will not be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such needed additional financing on a timely basis, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate. The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the consolidated financial statements do not necessarily purport to represent realizable or settlement values. The accompanying consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. Business Operations BRT develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT’s website is at www.biorestorative.com. The information contained in the website or connected thereto is not intended to be incorporated by reference into the accompanying financial statements or these footnotes. BRT is currently developing a Disc/Spine Program referred to as “brtxDISC”. Its lead cell therapy candidate, BRTX-100

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with GAAP. The summary of significant accounting policies presented below is designed to assist in understanding the Company’s consolidated financial statements. Such consolidated financial statements and accompanying notes are the representations of Company’s management, who is responsible for their integrity and objectivity. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Stem Pearls. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision, actual results could differ from these estimates which may cause the Company’s future results to be affected. Reclassifications Certain prior period balance sheet, statement of operations and statement of cash flows amounts have been reclassified to conform to the Company’s fiscal 2023 presentation. These reclassifications have no impact on the Company’s previously reported net loss. Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution. The Company maintains deposits in its cash account in excess of the Federal Depository Insurance Coverage limit of $ 250,000 The royalties related to the Company’s sublicense comprised 100% of the Company’s revenue during the years ended December 31, 2023 and 2022. See “Revenue Recognition” below. Revenue Recognition The Company accounts for revenue in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers The Company derives all of its revenue pursuant to a license agreement between the Company and a stem cell treatment company (“SCTC”) entered into in January 2012. In November 2022, the Company’s license rights under the agreement became exclusive. Pursuant to the license agreement, the SCTC granted to the Company a license to use certain intellectual property related to, among other things, stem cell disc procedures and the Company has granted to the SCTC a sublicense to use, and the right to sublicense to third parties the right to use, in certain locations in the United States and the Cayman Islands, certain of the licensed intellectual property. In consideration of the sublicenses, the SCTC has agreed to pay the Company royalties on a per disc procedure basis. The Company’s contracted transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company’s contracts have a single performance obligation which is not separately identifiable from other promises in the contracts and is, therefore, not distinct. The Company’s performance obligation is satisfied upon the transfer of risk of loss to the customer. The timing of the Company’s revenue recognition may differ from the timing of receiving royalty payments. A receivable is recorded when revenue is recognized prior to receipt of a royalty payment and the Company has an unconditional right to the royalty payment. Alternatively, when a royalty payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied. During the years ended December 31, 2023 and 2022, the Company recognized $ 145,800 119,800 Practical Expedients As part of ASC 606, the Company has adopted several practical expedients including: ● Significant Financing Component - the Company does not adjust the promised amount of consideration for the effects of a significant financing component since the Company expects, at contract inception, that the period between when the Company transfers a promised good or service to the customer and when the customer pays for that good or service will be one year or less. ● Unsatisfied Performance Obligations - all performance obligations related to contracts with a duration for less than one year; the Company has elected to apply the optional exemption provided in ASC Topic 606 and, therefore, is not required to disclose the aggregate amount of transaction price allocated to performance obligations that are unsatisfied or partially satisfied at the end of the reporting period. ● Right to Invoice - the Company has a right to consideration from a customer in an amount that corresponds directly with the value to the customer of the Company’s performance completed to date; the Company may recognize revenue in the amount to which the entity has a right to invoice. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. There were no Accounts Receivable Accounts receivable are carried at their contractual amounts, less a provision for current expected credit losses. The reserve represents the Company’s best estimate of expected credit losses it may experience in the Company’s receivable portfolio. Management estimates the allowance for credit losses based on an ongoing review of existing economic conditions, the financial conditions of the customers, historical trends in credit losses, and the amount and age of past due accounts. The Company writes off accounts receivable against the provision for current expected credit losses when a balance is determined to be uncollectible. The Company did no Property and Equipment Property and equipment are recorded at cost. Depreciation is computed using straight-line method over the estimated useful lives of the related assets, generally three fifteen years 3 5 Leasehold improvements are amortized over the lesser of (i) the useful life of the asset, or (ii) the remaining lease term. Maintenance and repairs are charged to expense as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment extends the useful life of the assets. At the time of retirement or other disposition of property and equipment, the cost and accumulated depreciation will be removed from the accounts and the resulting gain or loss, if any, will be reflected in operations. Intangible Assets The Company records its intangible assets at cost in accordance with ASC 350, Intangibles - Goodwill and Other Impairment of Long-Lived Assets The Company reviews long-lived assets, including definite-lived intangible assets and right-of-use assets from operating leases, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows or appraised values, depending on the nature of the assets. For the years ended December 31, 2023 and 2022, we determined that there was no Fair Value of Financial Instruments Fair value is defined as the amount that would be received for selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date and is measured using inputs in one of the following three categories: Level 1 measurements are based on unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to access. Valuation of these items does not entail a significant amount of judgment. Level 2 measurements are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or market data other than quoted prices that are observable for the assets or liabilities. Level 3 measurements are based on unobservable data that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. The Company considers cash and cash equivalents, investments held in marketable securities, accounts receivable, accounts payable and accrued liabilities to meet the definition of financial instruments. As of December 31, 2023 and 2022, the carrying amount of cash and cash equivalents, investments held in marketable securities, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to the relatively short period of time between their origination and their expected realization or payment. SCHEDULE OF FAIR VALUE RECURRING BASIS Fair value measurements at reporting date using: Fair value Quoted prices in active markets for identical liabilities Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Assets: Marketable securities as of December 31, 2023 $ 10,181,618 $ 10,181,618 - - Marketable securities as of December 31, 2022 $ 13,035,636 $ 13,035,636 - - During the years ended December 31, 2023 and 2022, the Company recognized aggregate dividend and interest income of $ 569,068 76,004 Net Loss per Common Share Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. The dilutive effect, if any, of stock options and warrants are calculated using the treasury stock method. All outstanding convertible preferred stock is considered common stock at the beginning of the period or at the time of issuance, if later, pursuant to the if-converted method. Since the effect of common stock equivalents is anti-dilutive with respect to losses, options, warrants, and convertible preferred stock have been excluded from the Company’s computation of diluted net loss per common share for the periods presented. The following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive due to the Company’s net loss position even though the exercise price could be less than the average market price of the common shares: SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES For the Years Ended December 31, 2023 2022 Stock options 1,466,892 864,639 Warrants 4,791,019 4,791,082 Unvested RSUs 97,827 201,870 Convertible Preferred Stock 1,398,158 1,518,158 Total 7,753,896 7,375,749 Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and then is recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period, on a straight-line basis. The Company computes the fair value of equity-classified warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are recorded as incurred as a reduction of amounts previously expensed. Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company utilizes ASC 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized. For uncertain tax positions that meet a “more likely than not” threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company’s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations. Leases The Company determines whether an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets and operating lease liabilities in our consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that it will exercise the option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses,

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 3 - PROPERTY AND EQUIPMENT Property and equipment consists of the following: SCHEDULE OF PROPERTY PLANT AND EQUIPMENT December 31, 2023 2022 Medical equipment $ 352,133 $ 352,133 Furniture and fixtures 123,486 123,486 Computer software and equipment 136,205 117,544 Office equipment 18,779 18,779 Manufacturing equipment 395,232 242,852 Leasehold improvements 342,048 342,048 1,367,883 1,196,842 Less: accumulated depreciation (1,011,828 ) (935,839 ) Property and equipment, net $ 356,055 $ 261,003 Total depreciation expense for the years ended December 31, 2023 and 2022 was $ 75,989 42,212

INTANGIBLE ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 4 - INTANGIBLE ASSETS The Company is a party to a license agreement with the SCTC (as amended) (the “SCTC Agreement”). Pursuant to the SCTC Agreement, the Company obtained, among other things, a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license from the SCTC to utilize or sublicense a certain method for culturing cells and a worldwide, exclusive, royalty-bearing license from the SCTC to utilize or sublicense a certain medical device patent for the administration of specific cells and/or cell products to the disc and/or spine (and other parts of the body). Pursuant to the license agreement with the SCTC, certain performance milestones (or payouts in lieu of performance milestones) had to be satisfied in order for the Company to maintain its exclusive rights with regard to the disc/spine technology. The Company did not timely satisfy the third of these performance milestones (which needed to be satisfied by February 2022). Accordingly, such rights became non-exclusive. However, the Company and the SCTC entered into an amended agreement under which the Company paid $ 175,000 51,370 117,030 In February 2017, the Company received authorization from the Food and Drug Administration (the “FDA”) to proceed with a Phase 2 clinical trial. In February 2022, the Company announced that the United States Patent and Trademark Office issued a notice of allowance for a patent application relating to the Company’s BRTX-100 clinical program. This patent was issued in March 2022. Intangible assets consist of the following: SCHEDULE OF INTANGIBLE ASSETS Patents and Trademarks Licenses Accumulated Amortization Total Balance as of January 1, 2022 $ 3,676 $ 1,301,500 $ (715,436 ) $ 589,740 Considertion transferred for license exclusivity - 292,030 - 292,030 Amortization expense - - (78,332 ) (78,332 ) Balance as of December 31, 2022 3,676 1,593,530 (793,768 ) 803,438 Amortization expense - - (89,746 ) (89,746 ) Balance as of December 31, 2023 $ 3,676 $ 1,593,530 $ (883,514 ) $ 713,692 Weighted average remaining amortization period at December 31, 2023 (in years) - 10.9 Amortization of intangible assets consists of the following: SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES Patents and Trademarks Licenses Accumulated Amortization Balance as of January 1, 2022 $ 3,676 $ 711,760 $ 715,436 Amortization expense - 78,332 78,332 Balance as of December 31, 2022 3,676 790,092 793,768 Amortization expense - 89,746 89,746 Balance as of December 31, 2023 $ 3,676 $ 879,838 $ 883,514 Amortization expense for the next five years is as follows: SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES For the Years Ending December 31, Total 2024 $ 89,746 2025 89,746 2026 89,746 2027 89,746 2028 89,746 Total $ 448,730

ACCRUED EXPENSES AND OTHER CURR

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	NOTE 5 - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consist of: SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES 2023 2022 December 31, 2023 2022 Accrued bonuses $ 638,000 $ 26,250 Accrued general and adminstrative expenses 73,686 103,822 Total accrued expenses and other current liabilities $ 711,686 $ 130,072

NOTES PAYABLE

NOTES PAYABLE	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
NOTES PAYABLE	Note 6 - NOTES PAYABLE A summary of the notes payable activity during the years ended December 31, 2023 and 2022 is presented below: SCHEDULE OF NOTES PAYABLE ACTIVITY Outstanding, Janaury 1, 2022 $ 250,000 Issuance - Forgiveness (250,000 ) Outstanding, December 31, 2022 - Issuance - Forgiveness - Outstanding, December 31, 2023 $ -

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
STOCKHOLDERS’ EQUITY	Note 7 - STOCKHOLDERS’ EQUITY Series A Preferred Stock On November 8, 2021, in connection with the Company’s public offering, the Company’s Board of Directors adopted a resolution allowing for the designation and issuance of 1,543,158 .01 0.001 1,543,158 Series B Preferred Stock Effective September 8, 2022, the Company issued 1,543,158 9.99 4.99 Dividends Series B holders shall be entitled to receive, when and as declared by the Board of Directors, dividends on a pari passu basis with the holders of the shares of Common Stock based upon the number of shares of Common Stock into which the Series B is then convertible. Voting Rights Series B holders shall be entitled to vote on all matters presented to the stockholders of the Company for a vote at a meeting of stockholders of the Company or a written consent in lieu of a meeting of stockholders of the Company, and shall be entitled to such number of votes for each share of Series B entitled to vote at such meetings or pursuant to such consent, voting together with the holders of shares of Common Stock and other shares of preferred stock who are entitled to vote, and not as a separate class, except as required by law. The number of votes to which the Series B holders shall be entitled to vote for each share of Series B shall equal the number of shares of Common Stock into which such Series B is then convertible; provided, however, that in no event shall a Series B holder be entitled to vote more than 9.99 Conversion Optional Conversion - Each share of Series B shall be convertible, at any time and from time to time, at the option of the Series B holder, into one share of Common Stock; 9.99 Automatic Conversion - From time to time, in the event that an event occurs which has the effect of reducing a Series B holder’s beneficial ownership of shares of Common Stock to less than 9.5 9.99 On October 25, 2022, Auctus converted 25,000 25,000 1,518,158 On April 4, 2023, Auctus converted 120,000 120,000 1,398,158 2021 Stock Incentive Plan On March 18, 2021, the Company’s Board of Directors adopted the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the “2021 Plan”). The 2021 Plan was approved by the Company’s stockholders on August 17, 2021. Pursuant to the 2021 Plan, a total of 1,175,000 1,175,000 2,500,000 2,500,000 3,850,000 Compensatory Common Stock Issuance During the year ended December 31, 2022, the Company issued 15,898 135,888 1,442 7,500 Sales of Common Stock In April 2023, the Company entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC (the “Sales Agent”) under which the Company currently has the ability to issue and sell shares of its Common Stock, from time to time, through the Sales Agent, up to an aggregate offering price of approximately $ 6,109,000 132,827 4.68 494,782 5,487,000 On July 13, 2023, the Company sold an aggregate of 685,033 3.03 1,853,990 Warrant and Option Valuation The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee option grants. The Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued. Warrant Activity Summary A summary of the warrant activity during the year ended December 31, 2023 is presented below: SCHEDULE OF WARRANT ACTIVITY Weighted Weighted Average Average Remaining Number of Exercise Life Warrants Price In Years Outstanding, January 31, 2023 4,791,082 $ 10.71 Granted - Exercised - Expired (63 ) 10,397 Outstanding, December 31, 2023 4,791,019 $ 10.57 2.9 Exercisable, December 31, 2023 4,791,019 $ 10.57 2.9 In applying the Black-Scholes option pricing model to warrants granted during 2022, the Company used the following assumptions: SCHEDULE OF WARRANTS GRANTED ASSUMPTIONS For the Year Ended December 31, 2022 Risk free interest rate 4.40 % Expected term (years) 5.00 Expected volatility 313.55 % Expected dividends 0.00 % The weighted average estimated fair value of the warrants granted during the year ended December 31, 2022 was $ 2.28 The following table presents information related to stock warrants at December 31, 2023: SCHEDULE OF STOCK WARRANTS Warrants Outstanding Warrants Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $ 2.92 51,370 3.9 51,370 $ 10.00 4,501,938 2.9 4,501,938 $ 12.00 235,970 2.9 235,970 $ 60.00 250 1.0 250 $ 800.00 869 0.8 869 $ 2,240.00 39 0.5 39 $ 2,800.00 264 0.3 264 $ 3,400.00 264 0.3 264 $ 4,000.00 55 0.1 55 4,791,019 4,791,019 Stock Options A summary of the option activity during the year ended December 31, 2023 is presented below: SCHEDULE OF STOCK OPTION ACTIVITY Weighted Weighted Average Average Remaining Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, January 31, 2023 864,639 $ 5.08 Granted 629,017 2.91 Exercised - Forfeited (26,764 ) 4.87 Outstanding, December 31, 2023 1,466,892 $ 4.11 7.4 $ - Exercisable, December 31, 2023 1,201,526 $ 4.33 7.1 $ - The weighted average grant date fair value of the stock options granted during the years ended December 31, 2023 and 2022 was approximately $ 3.00 4.88 The following table presents information related to stock options at December 31, 2023: SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 2.91 654,017 7.5 412,604 $ 5.08 812,875 6.9 788,922 1,466,892 1,201,526 In applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions: SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS For the Years Ended December 31, 2023 2022 Risk free interest rate 4.22 % 2.42 % Expected term (years) 3.50 3.50 Expected volatility 175.00 % 285.91 % Expected dividends 0.00 % 0.00 % Restricted Share Units Pursuant to the 2021 Plan, the Company may grant restricted stock units (“RSUs”) to employees, consultants or non-employee directors (“Eligible Recipients”). The number, terms and conditions of the RSUs that are granted to Eligible Recipients are determined on an individual basis by the 2021 Plan administrator. On the distribution date, the Company shall issue to the Eligible Recipient one unrestricted, fully transferable share of the Company’s common stock (or the fair market value of one such share in cash) for each vested and nonforfeitable RSU. A summary of the unvested RSUs as of December 31, 2023 is as follows: SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS Number of Shares Non-vested at January 1, 2023 201,870 Granted - Vested (104,043 ) Forfeited - Non-vested at December 31, 2023 97,827 Stock-Based Compensation Expense The following table presents information related to stock-based compensation expense: SCHEDULE OF STOCK OPTION EXPENSE For the Years Ended Unrecognized at Weighted Average Remaining Amortization December 31, December 31, Period 2023 2022 2023 (Years) General and administrative $ 7,782,967 $ 12,612,862 $ 1,557,071 0.83 Total $ 7,782,967 $ 12,612,862 $ 1,557,071 0.83

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 8 - INCOME TAXES The Company identified its federal and New York tax returns as its “major” tax jurisdictions. The Company is no longer subject to income tax income examinations by these tax authorities for taxable years ended December 31, 2018, and prior. The Company reviewed the prior New York state income tax filings and concluded that the prior year return will be amended to change the apportionment from zero to 100 At December 31, 2023, the Company had approximately $ 63,500,000 13,600,000 7,800,000 55,700,000 In accordance with Section 382 of the Internal Revenue Code, the usage of the Company’s net operating loss carryforwards are subject to annual limitations due to several greater than 50% ownership changes. The Section 382 limitations resulted in approximately $ 28,200,000 9,600,000 The Company has not performed a formal analysis for the year ended December 31, 2023, but it believes its ability to use such net operating losses and tax credit carryforwards in the future is subject to annual limitations due to change of control provisions under Sections 382 and 383 of the Internal Revenue Code, which will significantly impact its ability to realize these deferred tax assets. Management assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended December 31, 2023. For the period ended December 31, 2023, the Company has recorded a full valuation allowance recorded against the gross deferred tax asset balance as management believes that it is more likely than not that the results of operations will not generate sufficient taxable income to realize any of the deferred tax assets. As of the date of this filing, the Company has not filed its 2023 federal and state corporate income tax returns. The Company expects to file these documents as soon as practicable. The Company’s net deferred tax assets, liabilities and valuation allowance as of December 31, 2023 and 2022 are summarized as follows: SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES 2023 2022 December 31, 2023 2022 Deferred Tax Assets: Net Operating Loss Carryforwards $ 14,311,000 $ 13,200,000 Stock based Compensation 15,788,000 13,810,000 Research & Development Costs 1,676,000 655,000 Research & Development Credits 330,000 330,000 ROU Asset 25,000 - Other DTA 4,000 - Total Deferred Tax Assets 32,134,000 27,995,000 Deferred Tax Liabilities: Depreciation (122,000 ) (106,000 ) Intangible assets (47,000 ) (113,000 ) Lease Liability (39,000 ) - Other DTL (86,000 ) - Total Deferred Liabilities (294,000 ) (219,000 ) Net Deferred Tax Asset 31,840,000 27,776,000 Valuation Allowance $ (31,840,000 ) $ (27,776,000 ) Deferred Tax Asset, Net of Valuation Allowance $ - $ - Change in VA $ (4,064,000 ) $ (5,822,000 ) The income tax provision (benefit) as of December 31, 2023 and 2022 consists of the following: SCHEDULE OF INCOME TAX PROVISION (BENEFIT) 2023 2022 December 31, 2023 2022 Federal: Current $ - $ - Deferred - - State & Local: Current - - Deferred - - Total Income Tax Provision (Benefit) $ - $ - A reconciliation of the statutory federal income tax benefit to actual tax benefit for the years ended December 31, 2023 and 2022 is as follows: SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE 2023 2022 Federal Statutory Rate 21.0 % 21.0 % State rate Net, Net of Fed Benefit 1.3 % 5.6 % Permanent Difference -0.7 % -1.8 % Tax Return to Provision Adjustment -0.2 % 6.7 % Change in Valuation Allowance -21.4 % -31.5 % Effective tax rate 0.0 % 0.0 %

LEASES

LEASES	12 Months Ended
	Dec. 31, 2023
Leases
LEASES	NOTE 9 – LEASES The Company is a party to a lease for 6,800 132,600 149,260 the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor whereby the five-year extension term commenced on January 1, 2020 with annual base rent ranging between $ 153,748 173,060 When measuring lease liabilities for leases that were classified as operating leases, the Company discounted lease payments using its estimated incremental borrowing rate at August 1, 2019. The weighted average incremental borrowing rate applied was 12 The following table presents net lease cost and other supplemental lease information: SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION 2023 2022 For the Years Ended December 31, 2023 2022 Lease Costs Operating lease cost (cost resulting from lease payments) $ 168,028 $ 163,132 Net lease costs $ 168,028 $ 163,132 Operating lease - operating cash flows (fixed payments) $ 168,028 $ 163,132 Operating lease - operating cash flows (liability reduction) $ 139,328 $ 119,055 Non-current leases - right of use assets $ 151,447 $ 241,760 Current liabilities - operating lease liabilities $ 162,317 $ 139,328 Non-current liabilities - operating lease liabilities $ - $ 162,317 Future minimum payments under non-cancelable leases for operating leases for the remaining terms of the leases following the year ended December 31, 2023: SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES Fiscal Year Operating Leases 2024 $ 173,060 Total future minimum lease payments 173,060 Amount representing interest (10,743 ) Present value of net future minimum lease payments $ 162,317

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 10 - SUBSEQUENT EVENTS Warrant Exercise and Issuance On February 6, 2024, the Company entered into agreements with certain holders of its existing warrants exercisable for an aggregate of 3,351,580 2.33 8.1 3,351,580 2,000,000 1,351,580 In consideration for the immediate exercise of the Existing Warrants for cash and the payment of $ 0.125 2,513,686 2.43 In connection with the transaction described above, the Company entered into a financial advisory services agreement, dated February 5, 2024, with Roth Capital Partners, LLC (“Roth”), pursuant to which the Company has paid Roth a cash fee of approximately $ 528,000 Option Grants S 1,934,716 1.45 2,140,000 513,663 1,421,053 50

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with GAAP. The summary of significant accounting policies presented below is designed to assist in understanding the Company’s consolidated financial statements. Such consolidated financial statements and accompanying notes are the representations of Company’s management, who is responsible for their integrity and objectivity.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Stem Pearls. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision, actual results could differ from these estimates which may cause the Company’s future results to be affected.
Reclassifications	Reclassifications Certain prior period balance sheet, statement of operations and statement of cash flows amounts have been reclassified to conform to the Company’s fiscal 2023 presentation. These reclassifications have no impact on the Company’s previously reported net loss.
Concentrations	Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution. The Company maintains deposits in its cash account in excess of the Federal Depository Insurance Coverage limit of $ 250,000 The royalties related to the Company’s sublicense comprised 100% of the Company’s revenue during the years ended December 31, 2023 and 2022. See “Revenue Recognition” below.
Revenue Recognition	Revenue Recognition The Company accounts for revenue in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers The Company derives all of its revenue pursuant to a license agreement between the Company and a stem cell treatment company (“SCTC”) entered into in January 2012. In November 2022, the Company’s license rights under the agreement became exclusive. Pursuant to the license agreement, the SCTC granted to the Company a license to use certain intellectual property related to, among other things, stem cell disc procedures and the Company has granted to the SCTC a sublicense to use, and the right to sublicense to third parties the right to use, in certain locations in the United States and the Cayman Islands, certain of the licensed intellectual property. In consideration of the sublicenses, the SCTC has agreed to pay the Company royalties on a per disc procedure basis. The Company’s contracted transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company’s contracts have a single performance obligation which is not separately identifiable from other promises in the contracts and is, therefore, not distinct. The Company’s performance obligation is satisfied upon the transfer of risk of loss to the customer. The timing of the Company’s revenue recognition may differ from the timing of receiving royalty payments. A receivable is recorded when revenue is recognized prior to receipt of a royalty payment and the Company has an unconditional right to the royalty payment. Alternatively, when a royalty payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied. During the years ended December 31, 2023 and 2022, the Company recognized $ 145,800 119,800 Practical Expedients As part of ASC 606, the Company has adopted several practical expedients including: ● Significant Financing Component - the Company does not adjust the promised amount of consideration for the effects of a significant financing component since the Company expects, at contract inception, that the period between when the Company transfers a promised good or service to the customer and when the customer pays for that good or service will be one year or less. ● Unsatisfied Performance Obligations - all performance obligations related to contracts with a duration for less than one year; the Company has elected to apply the optional exemption provided in ASC Topic 606 and, therefore, is not required to disclose the aggregate amount of transaction price allocated to performance obligations that are unsatisfied or partially satisfied at the end of the reporting period. ● Right to Invoice - the Company has a right to consideration from a customer in an amount that corresponds directly with the value to the customer of the Company’s performance completed to date; the Company may recognize revenue in the amount to which the entity has a right to invoice.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. There were no
Accounts Receivable	Accounts Receivable Accounts receivable are carried at their contractual amounts, less a provision for current expected credit losses. The reserve represents the Company’s best estimate of expected credit losses it may experience in the Company’s receivable portfolio. Management estimates the allowance for credit losses based on an ongoing review of existing economic conditions, the financial conditions of the customers, historical trends in credit losses, and the amount and age of past due accounts. The Company writes off accounts receivable against the provision for current expected credit losses when a balance is determined to be uncollectible. The Company did no
Property and Equipment	Property and Equipment Property and equipment are recorded at cost. Depreciation is computed using straight-line method over the estimated useful lives of the related assets, generally three fifteen years 3 5 Leasehold improvements are amortized over the lesser of (i) the useful life of the asset, or (ii) the remaining lease term. Maintenance and repairs are charged to expense as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment extends the useful life of the assets. At the time of retirement or other disposition of property and equipment, the cost and accumulated depreciation will be removed from the accounts and the resulting gain or loss, if any, will be reflected in operations.
Intangible Assets	Intangible Assets The Company records its intangible assets at cost in accordance with ASC 350, Intangibles - Goodwill and Other
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews long-lived assets, including definite-lived intangible assets and right-of-use assets from operating leases, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows or appraised values, depending on the nature of the assets. For the years ended December 31, 2023 and 2022, we determined that there was no
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the amount that would be received for selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date and is measured using inputs in one of the following three categories: Level 1 measurements are based on unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to access. Valuation of these items does not entail a significant amount of judgment. Level 2 measurements are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or market data other than quoted prices that are observable for the assets or liabilities. Level 3 measurements are based on unobservable data that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. The Company considers cash and cash equivalents, investments held in marketable securities, accounts receivable, accounts payable and accrued liabilities to meet the definition of financial instruments. As of December 31, 2023 and 2022, the carrying amount of cash and cash equivalents, investments held in marketable securities, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to the relatively short period of time between their origination and their expected realization or payment. SCHEDULE OF FAIR VALUE RECURRING BASIS Fair value measurements at reporting date using: Fair value Quoted prices in active markets for identical liabilities Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Assets: Marketable securities as of December 31, 2023 $ 10,181,618 $ 10,181,618 - - Marketable securities as of December 31, 2022 $ 13,035,636 $ 13,035,636 - - During the years ended December 31, 2023 and 2022, the Company recognized aggregate dividend and interest income of $ 569,068 76,004
Net Loss per Common Share	Net Loss per Common Share Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. The dilutive effect, if any, of stock options and warrants are calculated using the treasury stock method. All outstanding convertible preferred stock is considered common stock at the beginning of the period or at the time of issuance, if later, pursuant to the if-converted method. Since the effect of common stock equivalents is anti-dilutive with respect to losses, options, warrants, and convertible preferred stock have been excluded from the Company’s computation of diluted net loss per common share for the periods presented. The following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive due to the Company’s net loss position even though the exercise price could be less than the average market price of the common shares: SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES For the Years Ended December 31, 2023 2022 Stock options 1,466,892 864,639 Warrants 4,791,019 4,791,082 Unvested RSUs 97,827 201,870 Convertible Preferred Stock 1,398,158 1,518,158 Total 7,753,896 7,375,749
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and then is recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period, on a straight-line basis. The Company computes the fair value of equity-classified warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are recorded as incurred as a reduction of amounts previously expensed.
Income Taxes	Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company utilizes ASC 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized. For uncertain tax positions that meet a “more likely than not” threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company’s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations.
Leases	Leases The Company determines whether an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets and operating lease liabilities in our consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that it will exercise the option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses,

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
SCHEDULE OF FAIR VALUE RECURRING BASIS	SCHEDULE OF FAIR VALUE RECURRING BASIS Fair value measurements at reporting date using: Fair value Quoted prices in active markets for identical liabilities Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Assets: Marketable securities as of December 31, 2023 $ 10,181,618 $ 10,181,618 - - Marketable securities as of December 31, 2022 $ 13,035,636 $ 13,035,636 - -
SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES	The following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive due to the Company’s net loss position even though the exercise price could be less than the average market price of the common shares: SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES For the Years Ended December 31, 2023 2022 Stock options 1,466,892 864,639 Warrants 4,791,019 4,791,082 Unvested RSUs 97,827 201,870 Convertible Preferred Stock 1,398,158 1,518,158 Total 7,753,896 7,375,749

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY PLANT AND EQUIPMENT	Property and equipment consists of the following: SCHEDULE OF PROPERTY PLANT AND EQUIPMENT December 31, 2023 2022 Medical equipment $ 352,133 $ 352,133 Furniture and fixtures 123,486 123,486 Computer software and equipment 136,205 117,544 Office equipment 18,779 18,779 Manufacturing equipment 395,232 242,852 Leasehold improvements 342,048 342,048 1,367,883 1,196,842 Less: accumulated depreciation (1,011,828 ) (935,839 ) Property and equipment, net $ 356,055 $ 261,003

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
SCHEDULE OF INTANGIBLE ASSETS	Intangible assets consist of the following: SCHEDULE OF INTANGIBLE ASSETS Patents and Trademarks Licenses Accumulated Amortization Total Balance as of January 1, 2022 $ 3,676 $ 1,301,500 $ (715,436 ) $ 589,740 Considertion transferred for license exclusivity - 292,030 - 292,030 Amortization expense - - (78,332 ) (78,332 ) Balance as of December 31, 2022 3,676 1,593,530 (793,768 ) 803,438 Amortization expense - - (89,746 ) (89,746 ) Balance as of December 31, 2023 $ 3,676 $ 1,593,530 $ (883,514 ) $ 713,692 Weighted average remaining amortization period at December 31, 2023 (in years) - 10.9
SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES	Amortization of intangible assets consists of the following: SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES Patents and Trademarks Licenses Accumulated Amortization Balance as of January 1, 2022 $ 3,676 $ 711,760 $ 715,436 Amortization expense - 78,332 78,332 Balance as of December 31, 2022 3,676 790,092 793,768 Amortization expense - 89,746 89,746 Balance as of December 31, 2023 $ 3,676 $ 879,838 $ 883,514
SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES	Amortization expense for the next five years is as follows: SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES For the Years Ending December 31, Total 2024 $ 89,746 2025 89,746 2026 89,746 2027 89,746 2028 89,746 Total $ 448,730

ACCRUED EXPENSES AND OTHER CU_2

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	Accrued expenses and other current liabilities consist of: SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES 2023 2022 December 31, 2023 2022 Accrued bonuses $ 638,000 $ 26,250 Accrued general and adminstrative expenses 73,686 103,822 Total accrued expenses and other current liabilities $ 711,686 $ 130,072

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
SCHEDULE OF NOTES PAYABLE ACTIVITY	A summary of the notes payable activity during the years ended December 31, 2023 and 2022 is presented below: SCHEDULE OF NOTES PAYABLE ACTIVITY Outstanding, Janaury 1, 2022 $ 250,000 Issuance - Forgiveness (250,000 ) Outstanding, December 31, 2022 - Issuance - Forgiveness - Outstanding, December 31, 2023 $ -

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
SCHEDULE OF WARRANT ACTIVITY	A summary of the warrant activity during the year ended December 31, 2023 is presented below: SCHEDULE OF WARRANT ACTIVITY Weighted Weighted Average Average Remaining Number of Exercise Life Warrants Price In Years Outstanding, January 31, 2023 4,791,082 $ 10.71 Granted - Exercised - Expired (63 ) 10,397 Outstanding, December 31, 2023 4,791,019 $ 10.57 2.9 Exercisable, December 31, 2023 4,791,019 $ 10.57 2.9
SCHEDULE OF WARRANTS GRANTED ASSUMPTIONS	In applying the Black-Scholes option pricing model to warrants granted during 2022, the Company used the following assumptions: SCHEDULE OF WARRANTS GRANTED ASSUMPTIONS For the Year Ended December 31, 2022 Risk free interest rate 4.40 % Expected term (years) 5.00 Expected volatility 313.55 % Expected dividends 0.00 %
SCHEDULE OF STOCK WARRANTS	The following table presents information related to stock warrants at December 31, 2023: SCHEDULE OF STOCK WARRANTS Warrants Outstanding Warrants Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $ 2.92 51,370 3.9 51,370 $ 10.00 4,501,938 2.9 4,501,938 $ 12.00 235,970 2.9 235,970 $ 60.00 250 1.0 250 $ 800.00 869 0.8 869 $ 2,240.00 39 0.5 39 $ 2,800.00 264 0.3 264 $ 3,400.00 264 0.3 264 $ 4,000.00 55 0.1 55 4,791,019 4,791,019
SCHEDULE OF STOCK OPTION ACTIVITY	A summary of the option activity during the year ended December 31, 2023 is presented below: SCHEDULE OF STOCK OPTION ACTIVITY Weighted Weighted Average Average Remaining Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, January 31, 2023 864,639 $ 5.08 Granted 629,017 2.91 Exercised - Forfeited (26,764 ) 4.87 Outstanding, December 31, 2023 1,466,892 $ 4.11 7.4 $ - Exercisable, December 31, 2023 1,201,526 $ 4.33 7.1 $ -
SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS	The following table presents information related to stock options at December 31, 2023: SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 2.91 654,017 7.5 412,604 $ 5.08 812,875 6.9 788,922 1,466,892 1,201,526
SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions: SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS For the Years Ended December 31, 2023 2022 Risk free interest rate 4.22 % 2.42 % Expected term (years) 3.50 3.50 Expected volatility 175.00 % 285.91 % Expected dividends 0.00 % 0.00 %
SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS	A summary of the unvested RSUs as of December 31, 2023 is as follows: SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS Number of Shares Non-vested at January 1, 2023 201,870 Granted - Vested (104,043 ) Forfeited - Non-vested at December 31, 2023 97,827
SCHEDULE OF STOCK OPTION EXPENSE	The following table presents information related to stock-based compensation expense: SCHEDULE OF STOCK OPTION EXPENSE For the Years Ended Unrecognized at Weighted Average Remaining Amortization December 31, December 31, Period 2023 2022 2023 (Years) General and administrative $ 7,782,967 $ 12,612,862 $ 1,557,071 0.83 Total $ 7,782,967 $ 12,612,862 $ 1,557,071 0.83

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES	The Company’s net deferred tax assets, liabilities and valuation allowance as of December 31, 2023 and 2022 are summarized as follows: SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES 2023 2022 December 31, 2023 2022 Deferred Tax Assets: Net Operating Loss Carryforwards $ 14,311,000 $ 13,200,000 Stock based Compensation 15,788,000 13,810,000 Research & Development Costs 1,676,000 655,000 Research & Development Credits 330,000 330,000 ROU Asset 25,000 - Other DTA 4,000 - Total Deferred Tax Assets 32,134,000 27,995,000 Deferred Tax Liabilities: Depreciation (122,000 ) (106,000 ) Intangible assets (47,000 ) (113,000 ) Lease Liability (39,000 ) - Other DTL (86,000 ) - Total Deferred Liabilities (294,000 ) (219,000 ) Net Deferred Tax Asset 31,840,000 27,776,000 Valuation Allowance $ (31,840,000 ) $ (27,776,000 ) Deferred Tax Asset, Net of Valuation Allowance $ - $ - Change in VA $ (4,064,000 ) $ (5,822,000 )
SCHEDULE OF INCOME TAX PROVISION (BENEFIT)	The income tax provision (benefit) as of December 31, 2023 and 2022 consists of the following: SCHEDULE OF INCOME TAX PROVISION (BENEFIT) 2023 2022 December 31, 2023 2022 Federal: Current $ - $ - Deferred - - State & Local: Current - - Deferred - - Total Income Tax Provision (Benefit) $ - $ -
SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE	A reconciliation of the statutory federal income tax benefit to actual tax benefit for the years ended December 31, 2023 and 2022 is as follows: SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE 2023 2022 Federal Statutory Rate 21.0 % 21.0 % State rate Net, Net of Fed Benefit 1.3 % 5.6 % Permanent Difference -0.7 % -1.8 % Tax Return to Provision Adjustment -0.2 % 6.7 % Change in Valuation Allowance -21.4 % -31.5 % Effective tax rate 0.0 % 0.0 %

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Dec. 31, 2023
Leases
SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION	The following table presents net lease cost and other supplemental lease information: SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION 2023 2022 For the Years Ended December 31, 2023 2022 Lease Costs Operating lease cost (cost resulting from lease payments) $ 168,028 $ 163,132 Net lease costs $ 168,028 $ 163,132 Operating lease - operating cash flows (fixed payments) $ 168,028 $ 163,132 Operating lease - operating cash flows (liability reduction) $ 139,328 $ 119,055 Non-current leases - right of use assets $ 151,447 $ 241,760 Current liabilities - operating lease liabilities $ 162,317 $ 139,328 Non-current liabilities - operating lease liabilities $ - $ 162,317
SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES	Future minimum payments under non-cancelable leases for operating leases for the remaining terms of the leases following the year ended December 31, 2023: SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES Fiscal Year Operating Leases 2024 $ 173,060 Total future minimum lease payments 173,060 Amount representing interest (10,743 ) Present value of net future minimum lease payments $ 162,317

ORGANIZATION, LIQUIDITY AND B_2

ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 14,415,484	$ 18,494,769
Share based compensation	7,782,967	12,612,862
Cash flows from operations	6,430,211	$ 5,913,100
Gross proceeds from warrant exercise	$ 8,100,000

SCHEDULE OF FAIR VALUE RECURRIN

SCHEDULE OF FAIR VALUE RECURRING BASIS (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Platform Operator, Crypto-Asset [Line Items]
Assets fair value disclosure	$ 10,181,618	$ 13,035,636
Fair Value, Inputs, Level 1 [Member]
Platform Operator, Crypto-Asset [Line Items]
Assets fair value disclosure	10,181,618	13,035,636
Fair Value, Inputs, Level 2 [Member]
Platform Operator, Crypto-Asset [Line Items]
Assets fair value disclosure
Fair Value, Inputs, Level 3 [Member]
Platform Operator, Crypto-Asset [Line Items]
Assets fair value disclosure

SCHEDULE OF WEIGHTED AVERAGE DI

SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	7,753,896	7,375,749
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,466,892	864,639
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,791,019	4,791,082
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	97,827	201,870
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,398,158	1,518,158

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
FDIC insured limit	$ 250,000
Revenue related to sublicense	145,800	$ 119,800
Cash equivalents	0	0
Allowance for doubtful accounts	0	0
Impairment of long-lived assets	0	0
Dividend and interest income	$ 569,068	$ 76,004
Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful lives	3 years
Minimum [Member] | Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful lives	3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful lives	15 years
Maximum [Member] | Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful lives	5 years

SCHEDULE OF PROPERTY PLANT AND

SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,367,883	$ 1,196,842
Less: accumulated depreciation	(1,011,828)	(935,839)
Property and equipment, net	356,055	261,003
Medical Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	352,133	352,133
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	123,486	123,486
Computer Software and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	136,205	117,544
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	18,779	18,779
Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	395,232	242,852
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 342,048	$ 342,048

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 75,989	$ 42,212

SCHEDULE OF INTANGIBLE ASSETS (

SCHEDULE OF INTANGIBLE ASSETS (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Net, beginning balance	$ 803,438	$ 589,740
Consideration transferred for license exclusivity		292,030
Finite Lived Intangible Assets, Amortization expense	(89,746)	(78,332)
Finite Lived Intangible Assets, Net, Ending Balance	713,692	803,438
Patents and Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, gross, beginning balance	3,676	3,676
Finite Lived Intangible Assets, Gross, Ending balance	$ 3,676	3,676
Finite Lived Intangible Assets, weighted average amortization period
License [Member]
Finite-Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, gross, beginning balance	$ 1,593,530	1,301,500
Finite Lived Intangible Assets, Accumulated amortization, beginning balance	(790,092)	(711,760)
Consideration transferred for license exclusivity		292,030
Finite Lived Intangible Assets, Amortization expense	(89,746)	(78,332)
Finite Lived Intangible Assets, Gross, Ending balance	1,593,530	1,593,530
Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance	$ (879,838)	(790,092)
Finite Lived Intangible Assets, weighted average amortization period	10 years 10 months 24 days
Accumulated Amortization [Member]
Finite-Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Accumulated amortization, beginning balance	$ (793,768)	(715,436)
Finite Lived Intangible Assets, Amortization expense	(89,746)	(78,332)
Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance	$ (883,514)	$ (793,768)

SCHEDULE OF FINITE LIVED INTANG

SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 89,746	$ 78,332
Patents and Trademark [Member]
Finite-Lived Intangible Assets [Line Items]
Beginning Balance	3,676	3,676
Amortization expense
Ending Balance	3,676	3,676
License [Member]
Finite-Lived Intangible Assets [Line Items]
Beginning Balance	790,092	711,760
Amortization expense	89,746	78,332
Ending Balance	879,838	790,092
Accumulated Amortization [Member]
Finite-Lived Intangible Assets [Line Items]
Beginning Balance	793,768	715,436
Amortization expense	89,746	78,332
Ending Balance	$ 883,514	$ 793,768

SCHEDULE OF FINITE LIVED INTA_2

SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)	Dec. 31, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 89,746
2025	89,746
2026	89,746
2027	89,746
2028	89,746
Total	$ 448,730

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Nov. 30, 2022	Dec. 31, 2023	Dec. 31, 2022
Payment to acquire intangible assets	$ 175,000		$ 175,000
Warrants issued		4,791,019
Warrant [Member]
Warrants issued	51,370
Fair value of warrants	$ 117,030

SCHEDULE OF ACCRUED EXPENSES AN

SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued bonuses	$ 638,000	$ 26,250
Accrued general and adminstrative expenses	73,686	103,822
Total accrued expenses and other current liabilities	$ 711,686	$ 130,072

SCHEDULE OF NOTES PAYABLE ACTIV

SCHEDULE OF NOTES PAYABLE ACTIVITY (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Loans payable outstanding beginning		$ 250,000
Issuances
Forgiveness		(250,000)
Loans payable outstanding ending

SCHEDULE OF WARRANT ACTIVITY (D

SCHEDULE OF WARRANT ACTIVITY (Details) - Warrant [Member]	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Warrants, Outstanding Beginning	4,791,082
Weighted Average Exercise Price, Outstanding beginning balance | $ / shares	$ 10.71
Number of Warrants, Granted
Number of Warrants, Exercised
Number of Warrants, Expired	(63)
Weighted Average Exercise Price, Expired | $ / shares	$ 10,397
Number of Warrants, Outstanding Ending	4,791,019
Weighted Average Exercise Price, Outstanding ending balance | $ / shares	$ 10.57
Weighted Average Remaining Life In Years, Outstanding	2 years 10 months 24 days
Number of Warrants, Exercisable Ending	4,791,019
Weighted Average Exercise Price, Exercisable | $ / shares	$ 10.57
Weighted Average Remaining Life In Years, Exercisable	2 years 10 months 24 days

SCHEDULE OF WARRANTS GRANTED AS

SCHEDULE OF WARRANTS GRANTED ASSUMPTIONS (Details) - Warrant [Member]	12 Months Ended
	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk free interest rate	4.40%
Expected term (years)	5 years
Expected volatility	313.55%
Expected dividends	0%

SCHEDULE OF STOCK WARRANTS (Det

SCHEDULE OF STOCK WARRANTS (Details)	Dec. 31, 2023 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants outstanding, number of warrants	4,791,019
Warrants exercisable, exercisable number of warrants	4,791,019
Exercise Price One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants outstanding, exercise price | $ / shares	$ 2.92
Warrants outstanding, number of warrants	51,370
Warrants exercisable, weighted average remaining life in years	3 years 10 months 24 days
Warrants exercisable, exercisable number of warrants	51,370
Exercise Price Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants outstanding, exercise price | $ / shares	$ 10
Warrants outstanding, number of warrants	4,501,938
Warrants exercisable, weighted average remaining life in years	2 years 10 months 24 days
Warrants exercisable, exercisable number of warrants	4,501,938
Exercise Price Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants outstanding, exercise price | $ / shares	$ 12
Warrants outstanding, number of warrants	235,970
Warrants exercisable, weighted average remaining life in years	2 years 10 months 24 days
Warrants exercisable, exercisable number of warrants	235,970
Exercise Price Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants outstanding, exercise price | $ / shares	$ 60
Warrants outstanding, number of warrants	250
Warrants exercisable, weighted average remaining life in years	1 year
Warrants exercisable, exercisable number of warrants	250
Exercise Price Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants outstanding, exercise price | $ / shares	$ 800
Warrants outstanding, number of warrants	869
Warrants exercisable, weighted average remaining life in years	9 months 18 days
Warrants exercisable, exercisable number of warrants	869
Exercise Price Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants outstanding, exercise price | $ / shares	$ 2,240
Warrants outstanding, number of warrants	39
Warrants exercisable, weighted average remaining life in years	6 months
Warrants exercisable, exercisable number of warrants	39
Exercise Price Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants outstanding, exercise price | $ / shares	$ 2,800
Warrants outstanding, number of warrants	264
Warrants exercisable, weighted average remaining life in years	3 months 18 days
Warrants exercisable, exercisable number of warrants	264
Exercise Price Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants outstanding, exercise price | $ / shares	$ 3,400
Warrants outstanding, number of warrants	264
Warrants exercisable, weighted average remaining life in years	3 months 18 days
Warrants exercisable, exercisable number of warrants	264
Exercise Price Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants outstanding, exercise price | $ / shares	$ 4,000
Warrants outstanding, number of warrants	55
Warrants exercisable, weighted average remaining life in years	1 month 6 days
Warrants exercisable, exercisable number of warrants	55

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details)	12 Months Ended
	Dec. 31, 2023 USD ($) $ / shares shares
Equity [Abstract]
Number of Options, Outstanding beginning	864,639
Weighted Average Exercise Price, Outstanding Beginning | $ / shares	$ 5.08
Number of Options, Granted	629,017
Weighted Average Exercise Price, Granted | $ / shares	$ 2.91
Number of Options, Exercised
Number of Options, Forfeited	(26,764)
Weighted Average Exercise Price, Forfeited | $ / shares	$ 4.87
Number of Options, Outstanding ending	1,466,892
Weighted Average Exercise Price, Outstanding Ending | $ / shares	$ 4.11
Weighted Average Remaining Life in Years Outstanding Ending	7 years 4 months 24 days
Intrinsic Value, Outstanding Ending | $
Number of Options, Exercisable Ending	1,201,526
Weighted Average Exercise Price Exercisable Ending | $ / shares	$ 4.33
Weighted Average Remaining Life in Years Exercisable Ending	7 years 1 month 6 days
Intrinsic Value, Outstanding Ending | $

SCHEDULE OF INFORMATION RELATED

SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	1,466,892	864,639
Options Exercisable, Exercisable Number of Options	1,201,526
Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 2.91
Options Outstanding, Outstanding Number of Options	654,017
Options Exercisable Weighted Average Remaining Life In Years	7 years 6 months
Options Exercisable, Exercisable Number of Options	412,604
Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 5.08
Options Outstanding, Outstanding Number of Options	812,875
Options Exercisable Weighted Average Remaining Life In Years	6 years 10 months 24 days
Options Exercisable, Exercisable Number of Options	788,922

SCHEDULE OF STOCK OPTION GRANTE

SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details) - Equity Option [Member]	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Offsetting Assets [Line Items]
Risk free interest rate	4.22%	2.42%
Expected term (years)	3 years 6 months	3 years 6 months
Expected volatility	175%	285.91%
Expected dividends	0%	0%

SCHEDULE OF UNVESTED RESTRICTED

SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2023 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares outstanding beginning	201,870
Number of shares vested
Number of shares forfeited	(104,043)
Number of shares outstanding ending	97,827

SCHEDULE OF STOCK OPTION EXPENS

SCHEDULE OF STOCK OPTION EXPENSE (Details) - Share-Based Payment Arrangement, Option [Member] - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Stock-based compensation expense	$ 7,782,967	$ 12,612,862
Unrecognized expense	$ 1,557,071
Weighted average remaining amortization period (years)	9 months 29 days
General and Administrative Expense [Member]
Stock-based compensation expense	$ 7,782,967	$ 12,612,862
Unrecognized expense	$ 1,557,071
Weighted average remaining amortization period (years)	9 months 29 days

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)					1 Months Ended	12 Months Ended
	Jul. 13, 2023	Apr. 04, 2023	Oct. 25, 2022	Sep. 08, 2022	Apr. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 10, 2021	Nov. 08, 2021	Mar. 18, 2021
Class of Stock [Line Items]
Preferred stock, par value						$ 0.01	$ 0.01
Common stock shares authorized						75,000,000	75,000,000
Vested common stock, shares						1,442	15,898
Aggregate common stock services rendered						$ 7,500	$ 135,888
Net proceeds offering price	$ 1,853,990					497,353
Proceeds from Issuance of Common Stock						1,853,990
Stock Issued During Period, Value, New Issues						$ 2,348,773
Sale of aggregate shares	685,033
Offering price	$ 3.03
Weighted average grant date fair value of stock options granted						$ 3	$ 4.88
Common Stock [Member]
Class of Stock [Line Items]
Sold shares of common stock						817,860
Stock Issued During Period, Value, New Issues						$ 81
Common Stock [Member] | Demand Sales Agreement [Member]
Class of Stock [Line Items]
Net proceeds offering price					$ 6,109,000
Warrant [Member]
Class of Stock [Line Items]
Weighted average estimated fair value of warrants granted							$ 2.28
2021 Stock Incentive Plan [Member]
Class of Stock [Line Items]
Number of shares of common stock authorized										1,175,000
2021 Stock Incentive Plan [Member] | Minimum [Member]
Class of Stock [Line Items]
Common stock shares authorized	2,500,000							1,175,000
2021 Stock Incentive Plan [Member] | Maximum [Member]
Class of Stock [Line Items]
Common stock shares authorized	3,850,000							2,500,000
A T M Program [Member] | Common Stock [Member]
Class of Stock [Line Items]
Sold shares of common stock						132,827
Weighted average price						$ 4.68
Proceeds from Issuance of Common Stock						$ 494,782
Stock Issued During Period, Value, New Issues						$ 5,487,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued									1,543,158
Preferred stock, par value									$ 0.01
Preferred stock, liquidation preference									$ 0.001
Preferred stock voting rights				4.99
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued				1,543,158
Preferred stock voting rights				9.99
Preferred stock voting percentage						9.99%
Preferred stock conversion term						Each share of Series B shall be convertible, at any time and from time to time, at the option of the Series B holder, into one share of Common Stock;
Series B Preferred Stock [Member] | Beneficial Ownership [Member]
Class of Stock [Line Items]
Preferred stock voting percentage						9.99%
Ownership percentage						9.50%
Common Class B [Member]
Class of Stock [Line Items]
Debt conversion, converted instrument, shares issued			25,000
Number of shares converted			1,518,158
Common Class B [Member] | Auctus Fund LLC [Member]
Class of Stock [Line Items]
Debt conversion, converted instrument, shares issued			25,000
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued						1,398,158	1,518,158
Preferred stock, shares outstanding						1,398,158	1,518,158
Series B Convertible Preferred Stock [Member] | Auctus Fund LLC [Member]
Class of Stock [Line Items]
Number of shares converted		120,000
Common Stock [Member] | Auctus Fund LLC [Member]
Class of Stock [Line Items]
Number of shares issued in conversion		120,000

SCHEDULE OF NET DEFERRED TAX AS

SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Deferred Tax Assets:
Net Operating Loss Carryforwards	$ 14,311,000	$ 13,200,000
Stock based Compensation	15,788,000	13,810,000
Research & Development Costs	1,676,000	655,000
Research & Development Credits	330,000	330,000
ROU Asset	25,000
Other DTA	4,000
Total Deferred Tax Assets	32,134,000	27,995,000
Deferred Tax Liabilities:
Depreciation	(122,000)	(106,000)
Intangible assets	(47,000)	(113,000)
Lease Liability	(39,000)
Other DTL	(86,000)
Total Deferred Liabilities	(294,000)	(219,000)
Net Deferred Tax Asset	31,840,000	27,776,000
Valuation Allowance	(31,840,000)	(27,776,000)
Deferred Tax Asset, Net of Valuation Allowance
Change in valuation allowance	$ (4,064,000)	$ (5,822,000)

SCHEDULE OF INCOME TAX PROVISIO

SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Federal:
Current
Deferred
State & Local:
Current
Deferred
Total Income Tax Provision (Benefit)

SCHEDULE OF STATUTORY FEDERAL I

SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Federal Statutory Rate	21%	21%
State rate Net, Net of Fed Benefit	1.30%	5.60%
Permanent Difference	(0.70%)	(1.80%)
Tax Return to Provision Adjustment	(0.20%)	6.70%
Change in Valuation Allowance	(21.40%)	(31.50%)
Effective tax rate	0%	0%

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating Loss Carryforwards [Line Items]
Prior year income taxes, percentage	100%
Operating loss carry-forwards not subject to expiration	$ 55,700,000
Deferred tax assets, operating loss carryforwards	14,311,000	$ 13,200,000
Expire from 2030 to 2038 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carry-forwards subject to expiration	7,800,000
Section 382 [Member]
Operating Loss Carryforwards [Line Items]
Federal net operating loss carry-forwards	$ 28,200,000	28,200,000
Income tax examination, description	In accordance with Section 382 of the Internal Revenue Code, the usage of the Company’s net operating loss carryforwards are subject to annual limitations due to several greater than 50% ownership changes.
Deferred tax assets, operating loss carryforwards	$ 9,600,000	9,600,000
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Federal net operating loss carry-forwards	$ 63,500,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Federal net operating loss carry-forwards		$ 13,600,000

SCHEDULE OF NET LEASE COST AND

SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Leases
Operating lease cost (cost resulting from lease payments)	$ 168,028	$ 163,132
Net lease costs	168,028	163,132
Operating lease - operating cash flows (fixed payments)	168,028	163,132
Operating lease - operating cash flows (liability reduction)	139,328	119,055
Non-current leases - right of use assets	151,447	241,760
Current liabilities - operating lease liabilities	162,317	139,328
Non-current liabilities - operating lease liabilities		$ 162,317

SCHEDULE OF FUTURE MINIMUM PAYM

SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES (Details)	Dec. 31, 2023 USD ($)
Leases
2024	$ 173,060
Total future minimum lease payments	173,060
Amount representing interest	(10,743)
Present value of net future minimum lease payments	$ 162,317

LEASES (Details Narrative)

LEASES (Details Narrative)	1 Months Ended	12 Months Ended
	Jun. 30, 2019 USD ($)	Dec. 31, 2023 USD ($) ft²
Weighted average incremental borrowing rate		12%
Melville Lease [Member]
Area of land | ft²		6,800
Lease extension description	the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor whereby the five-year extension term commenced on January 1, 2020 with annual base rent ranging between $153,748 and $173,060.
Melville Lease [Member] | Minimum [Member]
Rent expense	$ 153,748	$ 132,600
Melville Lease [Member] | Maximum [Member]
Rent expense	$ 173,060	$ 149,260

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)				12 Months Ended
	Feb. 06, 2024	Feb. 05, 2024	Jan. 01, 2024	Dec. 31, 2023	Dec. 31, 2022	Nov. 30, 2022
Subsequent Event [Line Items]
Warrants exercisable				4,791,019
Warrants outstanding				4,791,019
Cash fee for services				$ 7,500	$ 135,888
Common Stock [Member]
Subsequent Event [Line Items]
Purchase of common shares				817,860
Warrant [Member]
Subsequent Event [Line Items]
Warrants outstanding						51,370
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Warrants exercisable	3,351,580
Exercise price	$ 2.33
Warrants exercisable	$ 8,100,000
Grant options shares			1,934,716
Exercise price			$ 1.45
Grant options shares			$ 2,140,000
Options to purchase shares			513,663
Purchase of common shares			1,421,053
Purchase of common shares			50%
Subsequent Event [Member] | Common Stock [Member] | Roth Capital Partners LLC [Member]
Subsequent Event [Line Items]
Cash fee for services		$ 528,000
Subsequent Event [Member] | Common Stock [Member] | Private Placement [Member]
Subsequent Event [Line Items]
Warrants exercisable	2,513,686
Exercise price	$ 2.43
Warrants for cash and the payment	$ 0.125
Subsequent Event [Member] | Warrant [Member]
Subsequent Event [Line Items]
Warrants exercisable	2,000,000
Warrants outstanding	1,351,580